How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.08. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%. During the same period last year, the firm earned ($0.56) EPS.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA) , OPKO Health (OPK) , Amarin (AMRN) , QUALCOMM (QCOM) , VBI Vaccines (VBIV) , Sorrento Therapeutics (SRNE) , Advanced Micro Devices (AMD) , Axsome Therapeutics (AXSM) , Fulcrum Therapeutics (FULC) and AbbVie (ABBV) .

Positive News SentimentPositive News

NASDAQ:PRVB

Provention Bio (PRVB) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free PRVB Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $24.98
▼
$25.00
50-Day Range: $23.74
▼
$24.98
52-Week Range: $3.18
▼
$25.00

Volume: 9.12 million shs
Average Volume: 2.28 million shs
Market Capitalization: $2.37 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Provention Bio alerts:

Ad Altimetry

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

Just click here to watch my full uncensored interview.

About Provention Bio Stock (NASDAQ:PRVB)

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Ad Altimetry

I’m officially sounding the alarm.

Just click here to watch my full uncensored interview.

PRVB Stock News Headlines

December 29, 2023 | morningstar.com

Macrogenics Inc MGNX

May 1, 2023 | finance.yahoo.com

Sanofi/Provention: innovative diabetes drug is a good fit

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 29, 2023 | finance.yahoo.com

Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%

April 28, 2023 | seekingalpha.com

Sanofi completes Provention Bio acquisition

April 27, 2023 | finance.yahoo.com

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

April 27, 2023 | finanznachrichten.de

Sanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 26, 2023 | seekingalpha.com

Provention Bio gains after HSR waiting period for Sanofi deal expired

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 26, 2023 | benzinga.com

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

April 22, 2023 | finance.yahoo.com

PRVB Apr 2023 23.000 put

April 11, 2023 | msn.com

Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information

April 2, 2023 | finance.yahoo.com

Provention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimates

March 27, 2023 | bizjournals.com

Gaithersburg’s Novavax locks in consulting deal with outgoing R&D head

March 17, 2023 | benzinga.com

(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?

March 16, 2023 | finance.yahoo.com

Q4 2022 MacroGenics Inc Earnings Call

March 15, 2023 | benzinga.com

Provention Bio's Earnings Outlook

March 14, 2023 | msn.com

SMBC Nikko Downgrades Provention Bio (PRVB)

March 14, 2023 | msn.com

Jefferies Downgrades Provention Bio (PRVB)

March 14, 2023 | proactiveinvestors.com

Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal

March 14, 2023 | benzinga.com

Short Volatility Alert: Provention Bio Inc

March 14, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About Provention Bio

March 13, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi

March 13, 2023 | finance.yahoo.com

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

March 13, 2023 | msn.com

Sanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drug

March 13, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Provention Bio, Inc. Buyout

March 13, 2023 | businesswire.com

PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders

See More Headlines

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PRVB
CUSIP: N/A
CIK: 1695357
Web: www.proventionbio.com
Phone: (908) 428-9136
Fax: N/A
Employees: 82
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,570,000.00
Net Margins: -880.69%
Pretax Margin: -984.54%
Return on Equity: -103.36%
Return on Assets: -69.08%

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 1.93
Quick Ratio: 1.92

Sales & Book Value

Annual Sales: $12.90 million
Price / Sales: 183.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 17.84

Miscellaneous

Outstanding Shares: 94,780,000
Free Float: 82,365,000
Market Cap: $2.37 billion
Optionable: Not Optionable
Beta: 2.47

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Ashleigh W. Palmer
Chief Executive Officer & Director
Christina Yi
Chief Operating Officer
Thierry Chauche
Chief Financial Officer
Francisco Leon
Chief Scientific Officer
Eleanor Leni Ramos
Chief Medical Officer

Key Competitors

View All Competitors

PRVB Stock Analysis - Frequently Asked Questions

How were Provention Bio's earnings last quarter?: Provention Bio, Inc. (NASDAQ:PRVB) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.08. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $3.75 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%. During the same period last year, the firm earned ($0.56) EPS.
What other stocks do shareholders of Provention Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

This page (NASDAQ:PRVB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Provention Bio (PRVB) Stock Price, News & Analysis

About Provention Bio Stock (NASDAQ:PRVB)

PRVB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PRVB Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info